Cipla Limited Overview
Pro stress-test →Cipla Limited manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations across therapeutic areas, and is involved in consumer healthcare, biosimilars, and specialty businesses.
Strategic Profile
Pro stress-test →Cipla is the 3rd largest player in the private Rx market in South Asia and the fastest growing generic player in North America. The company holds leadership positions in respiratory care and top-5 rankings in urology and anti-infectives in the domestic market.
Competitive Landscape
Pro stress-test →Cipla operates in the Healthcare sector within Pharmaceuticals. The company competes with major Indian pharma players including Dr. Reddy's Laboratories, Sun Pharmaceutical, Lupin, and Aurobindo Pharma in generics and specialty segments, while facing North American competition in its growing US generic business.
Industry Context
Cipla Limited operates in Pharmaceuticals - Generics, Specialty, Biosimilars, and Consumer Healthcare.
Key facts
Founded: 1935 · Headquarters: Mumbai, India · Revenue: ~70.75B INR (Q3 FY26) · Market cap: ₹1.08 trillion (~$13B USD equivalent)